Anacor Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (ANAC) announced today that David Perry, the companys Chief Executive Officer, will provide a company overview at the Stifel Nicolaus 2012 Healthcare Conference on Wednesday, September 5, 2012 at 4:25 p.m. ET in Boston, Massachusetts.
The events will be webcast live and may be accessed under Events and Presentations on the Investors page of Anacors website at www.anacor.com. A replay will also be available for three months following the presentation.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered seven compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds - tavaborole, a topical antifungal for the treatment of onychomycosis and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered two other clinical product candidates, AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively. The Company has also discovered three compounds that it has out-licensed for further development - GSK 052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which is licensed to GlaxoSmithKline; AN8194, which is licensed to Eli Lilly and Company for an animal health indication; and AN5568, which is licensed to the Drugs for Neglected Diseases initiative for sleeping sickness. In addition, Anacor has a research and development agreement with Medicis Pharmaceuticals to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne. For more information, visit http://www.anacor.com.
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
Source: Anacor PharmaceuticalsCopyright Business Wire 2012